Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Oxford Biomedica appoints new finance chief
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica announced the appointment of Lucinda 'Lucy' Crabtree as its new chief financial officer and a member of the board on Wednesday. The London-listed firm said the transition would take effect on 2 September.
Stuart Paynter, who had served as CFO for almost seven years, would step down from his role and the board, and would transition away from the company following a suitable handover period.
OXB said Crabtree would bring extensive financial leadership experience to the company, having previously served as CFO of MorphoSys, where she led a finance team across the US and Germany until the company's acquisition by Novartis.
Before her tenure there, Crabtree was the CFO at Autolus Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company.
Her earlier career included roles as an investment professional at several notable institutions, including Woodford Investment Management, Panmure Gordon, Goldman Sachs, JPMorgan - originally Bear Stearns, and Jefferies.
Additionally, Crabtree had experience as a board observer at various private healthcare companies.
She holds a first-class Bachelor of Science degree in physiology and pharmacology from University College London, and a Ph.D. in pharmacology from the same institution.
"On behalf of the corporate executive team, I am delighted to welcome Lucy to Oxford Biomedica," said chief executive officer Dr Frank Mathias.
"Her unique skill set will be immensely valuable to us as we enter the next phase of our growth as a pure-play CDMO.
"I would also like to warmly thank Stuart for his dedicated service to OXB.
"Since joining the Company nearly seven years ago, Stuart has been instrumental in its success right the way through to the recent transformation of our business model."
At 1059 BST, shares in Oxford Biomedica were down 1.31% at 338.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.